Related Experiment Video
Updated: Jun 12, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Biomarkers in acute myocardial infarction
1Leicester National Institute for Health Research Cardiovascular Biomedical Research Unit, UK.
Novel biomarkers improve prediction of outcomes after myocardial infarction, but clinical trials are needed to prove they alter treatment effectiveness. Current use is limited to diagnosis and risk stratification, not guiding therapy.
Area of Science:
- Cardiology
- Biomarker Research
- Clinical Diagnostics
Background:
- Myocardial infarction (MI) leads to significant mortality and morbidity.
- Timely diagnosis and risk stratification are crucial for appropriate patient treatment.
- Biomarkers aid diagnosis and prognosis following acute coronary events.
Purpose of the Study:
- To review promising biomarkers for diagnosing and predicting outcomes in myocardial infarction and acute coronary syndromes.
- To highlight the role of novel biomarkers in risk stratification and potential for tailored therapy.
- To identify the translational gap between prognostic biomarker discovery and clinical application.
Main Methods:
- Literature review of diagnostic and prognostic biomarkers for acute myocardial infarction and acute coronary syndrome.
- Analysis of biomarkers including cardiac troponin, Heart-type Fatty Acid Binding Protein, copeptin, N-Terminal Pro-B-type Natriuretic Peptide, and others.
- Evaluation of clinical scoring systems like TIMI and GRACE for mortality risk prediction.
Main Results:
- Biomarkers like Heart-type Fatty Acid Binding Protein, copeptin, and troponin aid early MI diagnosis.
- N-Terminal Pro-B-type Natriuretic Peptide, ST2, and others predict death and heart failure post-MI.
- Novel biomarkers improve outcome prediction but haven't yet proven to alter therapeutic outcomes in trials.
Conclusions:
- Novel biomarkers offer valuable diagnostic and prognostic information for acute myocardial infarction and acute coronary syndromes.
- A multimarker approach combined with clinical scores enhances prognostic accuracy.
- Randomized trials are essential to validate the clinical utility of novel biomarkers in altering patient outcomes and guiding tailored therapy.
More Related Videos
10:12A Sensitive and Specific Quantitation Method for Determination of Serum Cardiac Myosin Binding Protein-C by Electrochemiluminescence Immunoassay
Published on: August 8, 2013
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome I: Introduction
Myocarditis II: Clinical Features and Diagnostic Tests